https://www.cellectar.com/ https://www.cellectar.com/about-us https://www.cellectar.com/about-us/management-team https://www.cellectar.com/about-us/board-of-directors https://www.cellectar.com/about-us/partnerships https://www.cellectar.com/our-science https://www.cellectar.com/our-science/lipid-rafts-in-cancer https://www.cellectar.com/our-science/pdc-platform-moa https://www.cellectar.com/our-science/tumor-types https://www.cellectar.com/developmental-programs https://www.cellectar.com/developmental-programs/beta-emitter https://www.cellectar.com/developmental-programs/auger-emitter https://www.cellectar.com/developmental-programs/alpha-emitter https://www.cellectar.com/clinical-trials https://www.cellectar.com/investors/news-events/press-releases/detail/386/cellectar-biosciences-reports-financial-results-for-year-ended-2025-and-provides-corporate-updates 2026-03-04T07:15:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/385/cellectar-biosciences-to-report-full-year-financial-results-and-host-a-conference-call-on-wednesday-march-4-2026 2026-02-25T08:05:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/384/cellectar-biosciences-expands-global-intellectual-property-estate 2026-02-17T08:05:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/383/cellectar-biosciences-to-highlight-strategic-initiatives-for-2026-at-upcoming-biotech-showcase-during-44th-annual-jp-morgan-healthcare-conference 2026-01-09T08:05:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/382/cellectar-biosciences-announces-strategic-supply-agreement-with-ionetix-for-actinium-225-and-astatine-211-to-advance-targeted-alpha-therapies 2025-12-16T08:05:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/381/cellectar-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-13T07:20:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/380/cellectar-biosciences-to-report-third-quarter-financial-results-and-host-a-conference-call-on-thursday-november-13-2025 2025-11-06T08:05:00-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/379/cellectar-biosciences-receives-rare-pediatric-disease-designation-from-u-s-food-and-drug-administration-for-iopofosine-i-131-in-relapsed-or-refractory-pediatric-high-grade-glioma 2025-10-27T08:30:22-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/378/cellectar-biosciences-presented-promising-preclinical-data-in-poster-presentation-at-the-american-association-for-cancer-research-aacr-special-conference-on-pancreatic-cancer-research 2025-10-14T08:30:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/377/cellectar-biosciences-inc-enters-into-agreements-to-raise-5-8-million 2025-10-07T08:30:11-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/376/cellectar-biosciences-announces-european-medicines-agency-ema-confirms-eligibility-to-file-for-conditional-marketing-authorization-cma-for-iopofosine-i-131-as-a-treatment-for-refractory-post-btki-waldenstrom-macroglobulinemia-wm 2025-10-06T07:00:04-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/375/cellectar-biosciences-presented-compelling-data-in-oral-session-and-panel-discussions-at-the-american-association-for-cancer-research-special-conference-on-discovery-and-innovation-in-pediatric-cancer 2025-09-30T08:30:09-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/374/cellectar-and-evestia-clinical-announce-partnership-to-support-auger-emitting-radiopharmaceutical-clinical-trial-in-triple-negative-breast-cancer-tnbc 2025-09-24T08:30:09-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/373/cellectar-biosciences-and-itm-enter-supply-agreement-for-gmp-grade-actinium-225 2025-09-11T08:05:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/372/cellectar-biosciences-to-participate-at-oppenheimer-3rd-annual-targeted-radiopharmaceutical-therapies-in-oncology-summit 2025-09-09T08:05:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/371/cellectar-biosciences-to-participate-in-multiple-upcoming-medical-meetings-and-industry-conferences-in-september 2025-09-05T08:45:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/370/cellectar-biosciences-to-present-data-in-poster-presentation-at-the-american-association-for-cancer-research-special-conference-on-advances-in-pancreatic-cancer-research 2025-09-03T08:05:00-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/369/cellectar-biosciences-to-present-data-in-oral-session-and-panel-discussions-at-the-american-association-for-cancer-research-special-conference-on-discovery-and-innovation-in-pediatric-cancer 2025-08-27T08:05:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/368/cellectar-biosciences-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update 2025-08-14T07:19:08-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/367/cellectar-biosciences-to-report-second-quarter-financial-results-and-host-a-conference-call-on-thursday-august-14-2025 2025-08-07T08:05:03-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/366/cellectar-biosciences-announces-closing-of-6-9-million-underwritten-public-offering-including-full-exercise-of-over-allotment-option 2025-07-02T16:15:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/365/cellectar-biosciences-announces-pricing-of-6-million-underwritten-public-offering 2025-07-01T09:25:00-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/364/cellectar-biosciences-and-u-s--based-nusano-enter-intomulti-isotope-supply-agreement 2025-06-26T08:05:00-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/363/cellectar-biosciences-submits-phase-1b-clinical-trial-protocol-to-us-food-and-drug-administration-for-clr-125-to-treat-triple-negative-breast-cancer-tnbc 2025-06-24T08:30:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/362/cellectar-biosciences-announces-one-for-thirty-reverse-stock-split 2025-06-18T16:30:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/361/cellectar-biosciences-provides-update-on-clover-2-phase-1-clinical-trial-of-iopofosine-i-131-in-pediatric-patients-with-relapsedrefractory-high-grade-glioma 2025-06-11T08:05:00-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/360/cellectar-biosciences-enters-into-common-stock-agreements-to-raise-2-5-million-priced-at-market-under-nasdaq-rules 2025-06-05T09:00:19-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/359/cellectar-granted-u-s-fda-breakthrough-therapy-designation-for-iopofosine-i-131-in-waldenstrom-macroglobulinemia-wm 2025-06-04T08:05:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/358/cellectar-biosciences-reports-first-quarter-2025-financial-results-and-provides-a-corporate-update 2025-05-13T07:05:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/357/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-a-conference-call-on-tuesday-may-13-2025 2025-05-07T08:05:00-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/356/cellectar-announces-plan-to-explore-strategic-alternatives 2025-04-30T08:05:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/355/cellectar-biosciences-reports-financial-results-for-year-ended-2024-and-provides-a-corporate-update 2025-03-13T07:05:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/354/cellectar-biosciences-to-present-at-the-37th-annual-roth-conference 2025-03-11T08:05:00-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/353/cellectar-biosciences-to-report-full-year-financial-results-and-host-a-conference-call-on-thursday-march-13-2025 2025-03-05T08:05:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/352/cellectar-biosciences-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference 2025-02-05T08:05:00-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/351/cellectar-biosciences-to-highlight-2025-strategic-initiatives-at-upcomingbiotech-showcase-during-the-jp-morgan-healthcare-conference 2025-01-12T18:00:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/350/cellectar-biosciences-provides-strategic-update-on-clinical-development-pipeline-programs-and-corporate-restructuring 2024-12-10T17:00:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/349/cellectar-biosciences-reports-financial-results-for-q3-2024-and-provides-a-corporate-update 2024-11-18T07:05:03-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/348/cellectar-biosciences-and-northstar-medical-radioisotopes-announce-partnership-for-supply-of-actinium-225 2024-11-14T08:05:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/347/cellectar-biosciences-and-spectronrx-partner-to-manufacture-novel-phospholipid-radioconjugate-for-the-treatment-of-cancer 2024-11-12T08:05:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/346/cellectar-biosciences-to-report-third-quarter-financial-results-and-host-a-conference-call-on-monday-november-18-2024 2024-11-11T16:05:14-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/345/cellectar-selected-to-present-new-data-from-phase-2-clover-wam-study-in-oral-session-at-ash-2024 2024-11-07T06:40:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/344/cellectar-biosciences-announces-compliance-regarding-filing-of-form-10-q 2024-11-01T17:00:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/343/iopofosine-i-131-featured-in-two-separate-presentations-at-12th-international-workshop-onwaldenstroms-macroglobulinemia 2024-08-26T06:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/342/cellectar-to-restate-previously-issued-financial-statements-company-announces-receipt-of-expected-delinquency-notification-letter-from-nasdaq 2024-08-23T17:00:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/341/cellectar-biosciences-reports-financial-results-for-q2-2024-and-provides-a-corporate-update 2024-08-13T06:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/339/cellectar-biosciences-to-announce-second-quarter-financial-results-and-host-a-conference-call-on-tuesday-august-13-2024 2024-08-08T17:32:58-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/338/cellectar-biosciences-iopofosine-i-131-exceeds-primary-endpoint-in-waldenstroms-macroglobulinemia-pivotal-study-with-78-of-major-response-patients-remaining-progression-free-at-18-months 2024-07-23T06:40:00-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/337/cellectar-biosciences-announces-exercise-of-tranche-b-warrants-and-purchase-of-new-warrants-for-approximately-19-4-million-with-the-potential-to-raise-up-to-an-additional-73-3-million 2024-07-22T06:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/336/cellectar-biosciences-to-host-key-opinion-leader-event-to-review-the-full-results-from-its-clover-wam-pivotal-trial-and-waldenstroms-macroglobulinemia-market-landscape 2024-06-27T06:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/335/cellectar-biosciences-and-city-of-hope-cancer-center-enter-collaboration-to-evaluate-iopofosine-i-131-in-mycosis-fungoides 2024-05-29T06:40:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/334/cellectar-biosciences-reports-financial-results-for-q1-2024-and-provides-a-corporate-update 2024-05-14T06:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/333/cellectar-biosciences-to-present-at-the-guggenheim-healthcare-talks-radiopharmaceuticals-day 2024-05-08T06:40:24-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/332/cellectar-biosciences-to-announce-first-quarter-financial-results-and-host-a-conference-call-on-tuesday-may-14-2024 2024-05-07T06:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/331/cellectar-biosciences-reports-financial-results-for-year-ended-2023-and-provides-a-corporate-update 2024-03-27T06:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/330/cellectar-biosciences-to-announce-2023-year-end-earnings-results-and-host-a-conference-call-on-wednesday-march27-2024 2024-03-20T06:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/329/cellectar-biosciences-to-present-at-the-36th-annual-roth-conference 2024-03-14T08:52:49-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/328/cellectar-biosciences-reports-high-rate-of-complete-remission-in-investigator-initiated-phase-i-study-of-iopofosine-in-combination-with-external-beam-radiotherapy-in-recurrent-head-and-neck-cancer 2024-03-04T06:40:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/327/cellectar-biosciences-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference 2024-02-07T06:40:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/326/cellectar-biosciences-announces-enrollment-of-the-first-patient-in-pediatric-high-grade-gliomas-phase-1b-clinical-study 2024-01-30T06:40:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/325/cellectar-biosciences-announces-tranche-a-warrants-fully-exercised-providing-proceeds-of-44-1-million 2024-01-25T06:40:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/324/cellectar-biosciences-reports-complete-central-nervous-system-cns-clearance-in-relapsedrefractory-waldenstroms-macroglobulinemia-patient 2024-01-22T06:40:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/323/cellectar-biosciences-broadens-pipeline-with-targetedalpha-therapy-tat-for-solid-tumors-and-releases-promising-preclinical-data 2024-01-16T06:40:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/322/cellectar-biosciences-to-host-conference-call-with-texas-oncology-hematologist-m-yair-levy-m-d-on-january-19-2024-to-discuss-iopofosine-i-131-pivotal-topline-results 2024-01-12T06:44:16-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/321/cellectar-biosciences-partners-with-miba-a-data-subsidiary-of-american-oncology-network-to-advance-the-treatment-of-waldenstroms-macroglobulinemia-in-the-community-setting 2024-01-11T06:40:00-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/320/cellectar-biosciences-announces-positive-topline-data-achieving-primary-endpoint-in-pivotal-clinical-study-of-iopofosine-i-131-in-waldenstroms-macroglobulinemia 2024-01-08T06:30:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/319/cellectar-biosciences-to-announce-top-line-data-from-wm-pivotal-trial-on-january-8-2024 2024-01-03T08:30:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/318/cellectar-biosciences-expands-iopofosine-i-131-collaboration-with-wisconsin-alumni-research-foundation 2023-12-20T14:18:27-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/317/cellectar-biosciences-strengthens-intellectual-property-protection-for-its-pdc-platform 2023-12-12T08:30:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/316/cellectar-biosciences-to-present-at-the-targeted-radiopharmaceuticals-summit-europe 2023-12-05T08:30:03-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/315/cellectar-to-release-top-line-data-from-wm-pivotal-trial-during-the-jp-morgan-healthcare-conference-the-week-of-january-8-2024 2023-11-02T07:30:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/314/cellectar-biosciences-partners-with-florida-cancer-specialists-research-institute-to-support-the-treatment-of-waldenstroms-macroglobulinemia-in-the-community-setting 2023-10-25T08:00:05-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/313/cellectar-biosciences-to-announce-third-quarter-earnings-results-and-host-a-conference-call-on-thursday-november-2-2023 2023-10-24T08:00:04-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/312/cellectar-biosciences-expands-commercialization-leadership-team-ahead-of-pivotal-data-for-iopofosine-i-131-in-waldenstroms-macroglobulinemia 2023-10-17T08:00:04-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/311/cellectar-biosciences-expands-global-intellectual-property-portfolio-with-four-patent-grants 2023-10-02T06:35:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/310/cellectar-biosciences-receives-european-medicines-agency-priority-medicines-prime-designation-for-iopofosine-for-waldenstroms-macroglobulinemia 2023-09-18T08:40:25-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/309/cellectar-biosciences-announces-closing-of-up-to-approximately-103-million-private-placement-financing 2023-09-11T06:30:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/308/cellectar-biosciences-announces-up-to-approximately-103-million-private-placement-financing 2023-09-05T10:18:26-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/307/cellectar-reports-financial-results-for-second-quarter-2023-and-provides-a-corporate-update 2023-08-14T08:40:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/305/cellectar-provides-a-research-and-development-program-summary 2023-06-12T08:30:04-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/304/update----cellectar-reports-financial-results-for-first-quarter-2023-and-provides-a-corporate-update 2023-05-04T09:23:00-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/303/cellectar-reports-financial-results-for-first-quarter-2023-and-provides-a-corporate-update 2023-05-04T08:40:08-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/302/cellectar-reports-financial-results-for-year-ended-2022-and-provides-a-corporate-update 2023-03-09T08:40:06-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/301/cellectar-to-participate-at-upcoming-banking-conferences 2023-03-08T16:05:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/300/cellectar-biosciences-reports-complete-response-in-a-relapsedrefractory-cns-lymphoma-patient 2023-02-28T08:30:11-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/299/cellectar-biosciences-hires-dr-andrei-shustov-as-new-senior-vice-president-medical 2023-02-15T08:30:04-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/298/cellectar-biosciences-announces-shane-lea-as-chief-commercial-officer 2022-11-30T08:30:05-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/297/cellectar-biosciences-announces-presentation-of-data-on-clr-12120-series-of-targeted-alpha-emitting-therapies-at-the-13th-annual-world-adc-conference 2022-11-21T08:30:08-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/296/cellectar-announces-resolution-of-breach-of-contract-and-intellectual-property-dispute 2022-11-16T08:30:06-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/295/cellectar-reports-financial-results-for-third-quarter-2022-and-provides-a-corporate-update 2022-11-03T08:30:04-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/294/cellectar-biosciences-announces-closing-of-concurrent-registered-direct-and-private-placement-offerings-of-approximately-10-7-million-priced-at-the-market-under-nasdaq-rules 2022-10-25T16:30:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/293/cellectar-biosciences-announces-concurrent-registered-direct-and-private-placement-offerings-of-approximately-10-7-million-priced-at-the-market-under-nasdaq-rules 2022-10-21T08:30:06-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/292/cellectar-awarded-2-million-grant-to-expand-its-ongoing-phase-1-study-of-iopofosine-i-131-in-pediatric-brain-tumors 2022-09-22T08:30:13-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/291/cellectar-announces-publication-of-data-from-its-expansion-cohort-of-the-phase-ii-clover-1-study-iopofosine-i-131-in-relapsedrefractory-multiple-myeloma-in-natures-blood-cancer-journal 2022-09-13T08:30:14-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/290/cellectar-reports-financial-results-for-second-quarter-2022 2022-08-05T08:30:14-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/289/cellectar-announces-stock-consolidation 2022-07-21T16:15:08-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/288/cellectar-reports-financial-results-for-first-quarter-2022-and-provides-a-corporate-update 2022-05-10T08:30:11-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/287/cellectar-biosciences-announces-positive-dmc-review-of-pivotal-trial-of-iopofosine-in-waldenstroms-macroglobulinemia 2022-04-26T08:00:19-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/286/cellectar-biosciences-announces-key-commercial-team-appointments 2022-04-12T08:30:07-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/285/cellectar-reports-financial-results-for-year-ended-december-2021-and-provides-a-corporate-update 2022-03-21T08:30:10-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/284/cellectar-to-participate-at-upcoming-banking-conferences 2022-03-10T16:05:30-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/283/cellectar-biosciences-announces-executive-leadership-changes 2022-02-23T08:00:12-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/282/cellectar-to-participate-in-fireside-chat-at-the-h-c-wainwright-bioconnect-conference 2022-01-04T08:30:05-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/281/cellectar-presented-data-from-its-ongoing-phase-2-clover-1-study-of-iopofosine-i-131-at-the-63rd-ash-annual-meeting-and-exposition 2021-12-13T08:30:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/280/cellectar-biosciences-announces-poster-presentation-at-the-63rd-american-society-for-hematology-annual-meeting-and-exposition 2021-12-08T08:30:03-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/279/cellectars-iopofosine-i-131-exhibits-signals-of-efficacy-in-phase-i-study-for-pediatric-brain-and-solid-tumors 2021-11-16T08:30:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/278/cellectar-reports-financial-results-for-the-third-quarter-2021-and-provides-a-corporate-update 2021-11-08T08:30:04-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/277/cellectar-appoints-laurence-reilly-m-d-ll-m-interim-chief-medical-officer 2021-11-02T08:30:03-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/276/cellectar-announces-innovative-concierge-service-for-patients-participating-in-its-clinical-studies 2021-10-25T09:00:07-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/275/preliminary-data-with-iopofosine-i-131-in-combination-with-external-beam-radiation-suggests-safety-and-tolerability-in-relapsed-or-refractory-head-and-neck-cancer 2021-09-22T08:30:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/274/cellectar-to-participate-in-the-oppenheimer-fall-healthcare-life-sciences-medtech-summit 2021-09-15T16:01:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/273/cellectar-awarded-2-0-million-phase-ii-nih-sbir-grant-to-support-pivotal-study-of-iopofosine-i-131-in-waldenstroms-macroglobulinemia 2021-08-18T08:30:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/272/cellectar-announces-manufacturing-and-supply-agreement-with-evergreen-theragnostics-for-clr-131-now-known-as-iopofosine-i-131 2021-08-16T08:30:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/271/cellectar-reports-financial-results-for-the-second-quarter-2021-and-provides-a-corporate-update 2021-08-09T08:30:03-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/270/cellectar-announces-expansion-of-ongoing-collaboration-agreement-with-intocell-inc 2021-07-13T09:00:05-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/269/cellectar-announces-a-co-development-and-commercialization-collaboration-with-legochembio-for-new-small-molecule-phospholipid-drug-conjugates-pdcs 2021-07-12T08:30:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/268/cellectar-to-participate-in-the-ladenburg-thalmann-2021-virtual-healthcare-conference 2021-07-08T08:30:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/267/cellectar-announces-the-election-of-dr-asher-alban-chanan-khan-to-its-board-of-directors 2021-06-24T08:30:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/266/cellectar-presents-data-in-waldenstroms-macroglobulinemia-in-poster-at-the-2021-american-society-of-clinical-oncology-asco-annual-meeting 2021-06-04T09:00:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/265/cellectar-announces-poster-presentation-of-clr-131-data-in-waldenstroms-macroglobulinemia-at-the-2021-american-society-of-clinical-oncology-asco-annual-meeting 2021-05-20T08:30:03-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/264/cellectar-to-participate-at-the-oppenheimer-rare-orphan-disease-summit-on-may-21-2021 2021-05-14T09:00:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/263/cellectar-reports-financial-results-for-the-first-quarter-2021-and-provides-a-corporate-update 2021-05-10T08:30:04-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/262/cellectar-strengthens-global-ip-position-with-phospholipid-drug-conjugate-composition-of-matter-patent-in-eurasia-australia-and-mexico 2021-04-27T08:39:42-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/261/cellectar-to-participate-at-upcoming-institutional-investor-conferences 2021-03-11T08:30:05-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/260/cellectar-granted-japanese-composition-of-matter-patent-for-its-phospholipid-ether-drug-conjugates 2021-03-09T09:00:08-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/259/cellectar-to-participate-at-upcoming-institutional-investor-conferences 2021-03-05T08:30:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/258/cellectar-reports-financial-results-for-year-ended-december-31-2020-and-provides-a-corporate-update 2021-03-02T08:30:06-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/257/cellectar-to-present-at-bio-ceo-investor-digital-conference 2021-02-10T08:30:03-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/256/cellectar-receives-orphan-drug-designation-from-the-european-commission-for-clr-131-in-waldenstroms-macroglobulinemia 2021-01-27T08:30:04-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/255/cellectar-initiates-pivotal-trial-of-clr-131-in-waldenstroms-macroglobulinemia 2021-01-12T08:30:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/254/cellectar-biosciences-announces-closing-of-24-5-million-underwritten-public-offering-and-20-5-million-concurrent-private-placement 2020-12-28T16:05:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/253/cellectar-biosciences-announces-pricing-of-24-5-million-underwritten-public-offering-and-20-5-million-concurrent-private-placement 2020-12-23T08:38:46-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/252/cellectar-biosciences-announces-proposed-underwritten-public-offering-and-concurrent-private-placement 2020-12-22T17:27:56-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/251/cellectar-reports-third-quarter-2020-financial-results-and-provides-a-corporate-update 2020-11-09T08:44:15-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/250/cellectar-biosciences-clr-131-demonstrates-preliminary-activity-in-phase-i-study-for-pediatric-brain-and-solid-tumors 2020-11-05T09:00:05-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/249/cellectar-biosciences-to-present-at-two-upcoming-investor-conferences 2020-09-10T08:00:12-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/248/cellectar-reports-data-on-clr-131-phase-2-clover-1-study-in-triple-class-refractory-multiple-myeloma-patients 2020-09-09T08:00:17-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/247/cellectar-presents-poster-at-the-aacr-virtual-meeting-advances-in-malignant-lymphoma 2020-08-17T10:01:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/246/cellectar-reports-second-quarter-2020-financial-results-and-provides-a-corporate-update 2020-08-10T08:00:08-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/245/cellectar-announces-poster-presentation-at-the-international-symposium-on-pediatric-neuro-oncology-ispno-annual-meeting 2020-08-04T08:00:16-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/244/cellectar-announces-poster-presentation-of-clinical-data-at-the-american-association-of-cancer-research-aacr-annual-meeting 2020-07-21T08:00:09-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/243/cellectar-appoints-dr-john-friend-as-chief-medical-officer 2020-07-01T08:00:08-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/242/cellectar-to-be-granted-eu-patent-for-phospholipid-ether-ple-analogs-as-cancer-targeting-drug-vehicles 2020-06-11T08:30:06-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/241/cellectar-biosciences-announces-closing-of-20-million-underwritten-public-offering 2020-06-05T16:01:03-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/240/cellectar-biosciences-announces-pricing-of-20-million-underwritten-public-offering 2020-06-03T09:00:10-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/239/cellectar-granted-sme-status-by-the-european-medicines-agency 2020-06-01T08:00:10-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/238/cellectar-receives-fda-fast-track-designation-forclr-131-in-lymphoplasmacytic-lymphomawaldenstroms-macroglobulinemia 2020-05-26T09:50:13-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/237/cellectar-granted-composition-of-matter-and-use-patent-in-europe-for-clr-131 2020-05-14T09:45:01-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/236/cellectar-reports-first-quarter-2020-financial-resultsand-provides-a-corporate-update 2020-05-07T08:15:08-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/235/cellectar-reports-financial-results-for-year-ended-december-31-2019-and-provides-a-corporate-update 2020-03-09T08:00:06-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/234/cellectar-biosciences-announces-clr-131-achieves-primary-efficacy-endpoints-from-its-phase-2-clover-1-study-in-relapsedrefractory-b-cell-lymphomas-and-completion-of-the-phase-1-relapsedrefractory-multiple-myeloma-dose-escalation-study 2020-02-19T08:00:09-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/233/cellectar-biosciences-to-host-a-clr-131-clinical-data-call-with-its-phase-2-lead-investigator-on-february-19-2020 2020-01-09T08:00:12-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/232/cellectar-appoints-dr-igor-grachev-as-chief-medical-officer 2020-01-07T08:00:06-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/231/cellectar-receives-orphan-drug-designation-for-clr-131-in-lymphoplasmacytic-lymphoma-lpl 2020-01-06T08:00:11-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/230/cellectar-biosciences-to-present-at-biotech-showcase-2020 2019-12-19T08:00:13-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/229/cellectar-announces-data-from-20-patients-receiving-a-single-25mcim2-bolus-dose-of-clr-131-in-the-phase-2-clover-1-study 2019-12-16T08:00:21-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/228/cellectar-presents-poster-at-the-american-association-for-cancer-research-aacr-san-antonio-breast-cancer-symposium 2019-12-13T08:30:07-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/227/fractionated-dosing-of-clr-131-in-patients-with-relapsed-or-refractory-multiple-myeloma-presented-at-the-61st-annual-american-society-of-hematology-conference 2019-12-09T08:30:12-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/226/cellectar-announces-oral-presentation-at-the-61st-annual-american-society-of-hematology-conference 2019-12-02T08:30:16-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/225/cellectar-reports-third-quarter-2019-financial-results-and-provides-a-corporate-update 2019-11-12T08:00:10-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/224/cellectar-presents-a-new-phospholipid-drug-conjugate-pdc-at-the-2019-aacr-nci-eortc-molecular-targets-and-cancer-therapeutics-conference 2019-10-30T08:00:09-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/223/cellectar-announces-poster-at-the-2019-aacr-nci-eortc-molecular-targets-and-cancer-therapeutics-conference-in-boston 2019-10-17T08:00:16-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/222/cellectar-presents-poster-at-the-cancer-research-uk-aacr-joint-conference-on-engineering-and-physical-sciences-in-oncology 2019-10-15T08:00:24-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/221/cellectar-announces-presentation-at-the-cancer-research-uk-aacr-joint-conference-on-engineering-and-physical-sciences-in-oncology 2019-10-08T08:00:19-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/220/cellectar-presents-data-from-dlbcl-cohort-of-its-phase-2-clover-1-study-at-the-european-society-for-medical-oncology-esmo-congress 2019-09-30T08:30:11-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/219/cellectar-receives-orphan-drug-designation-from-the-european-commission-for-clr-131-in-multiple-myeloma 2019-09-24T08:00:31-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/218/cellectar-biosciences-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference 2019-09-19T08:30:07-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/217/cellectar-presents-data-from-cohort-6-of-its-clr-131-phase-1-study-in-patients-with-relapsed-or-refractory-multiple-myeloma 2019-09-16T08:30:09-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/216/cellectar-announces-oral-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2019 2019-09-10T08:00:37-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/215/cellectar-announces-late-breaker-poster-presentation-at-the-17th-international-myeloma-workshop 2019-09-04T08:00:06-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/214/cellectar-appoints-dov-elefant-as-chief-financial-officer 2019-08-15T08:30:07-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/213/clr-131-advances-to-second-malignant-brain-tumor-cohort-of-ongoing-pediatric-phase-1-study 2019-08-14T08:30:14-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/212/cellectar-reports-second-quarter-2019-financial-results-and-provides-a-corporate-update 2019-08-12T08:00:10-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/211/cellectar-receives-fda-fast-track-designation-for-clr-131-in-diffuse-large-b-cell-lymphoma 2019-07-09T08:30:41-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/210/cellectar-expands-third-cohort-of-its-phase-2-clover-1-study-of-clr-131 2019-05-21T08:30:12-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/209/cellectar-biosciences-announces-closing-of-10-0-million-financing 2019-05-20T16:12:57-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/208/cellectar-biosciences-announces-10-0-million-financing 2019-05-16T08:53:37-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/207/clr-131-achieves-50-overall-response-rate-in-cohort-6-of-ongoing-phase-1-study-in-relapsed-or-refractory-multiple-myeloma 2019-05-15T08:30:16-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/206/cellectar-receives-fda-fast-track-designation-for-clr-131-in-relapsed-or-refractory-multiple-myeloma 2019-05-13T08:00:19-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/205/cellectar-reports-first-quarter-2019-financial-results-and-provides-a-corporate-update 2019-05-06T08:00:14-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/204/fda-grants-exemption-to-import-alert-for-cellectars-clr-131-in-pediatric-and-adolescent-patients 2019-03-19T08:30:05-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/203/cellectar-reports-financial-results-for-year-ended-december-31-2018-and-provides-a-corporate-update 2019-02-26T08:30:14-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/202/cellectar-reports-positive-top-line-response-rate-of-30-from-rr-multiple-myeloma-cohort-in-ongoing-phase-2-study-of-clr-131 2019-02-25T08:30:11-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/201/cellectar-biosciences-to-present-at-the-annual-bio-ceo-investor-conference 2019-02-05T08:30:05-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/200/cellectar-biosciences-to-present-at-nobleconxv-noble-capital-markets-fifteenth-annual-investor-conference 2019-01-23T08:00:23-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/199/cellectar-provides-update-on-phase-1-trial-of-clr-131-in-relapsedrefractory-multiple-myeloma 2019-01-07T08:30:22-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/198/cellectar-biosciences-to-present-at-the-biotech-showcase 2019-01-03T08:30:11-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/197/cellectar-granted-japanese-patent-for-clr-131 2018-12-11T08:30:10-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/196/cellectar-initiates-cohort-6-of-phase-1b-trial-evaluating-clr-131-in-relapsedrefractory-multiple-myeloma 2018-12-04T08:30:09-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/195/cellectar-reports-third-quarter-2018-financial-results-and-provides-business-update 2018-11-13T08:30:18-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/194/cellectar-announces-fda-grants-exemption-to-import-alert-for-clr-131-hematology-studies 2018-11-12T08:30:11-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/193/cellectar-announces-overall-survival-exceeding-19-months-in-phase-1b-trial-with-clr-131-in-relapsedrefractory-multiple-myeloma 2018-10-02T08:00:19-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/192/cellectar-biosciences-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference 2018-09-27T08:30:09-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/191/cellectars-clr-131-receives-fda-orphan-drug-designation-for-the-treatment-of-pediatric-osteosarcoma 2018-09-25T08:30:10-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/190/cellectar-biosciences-provides-an-update-on-the-fda-import-alert 2018-09-24T08:00:14-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/189/fda-grants-rare-pediatric-disease-designation-to-cellectar-biosciences-clr-131-for-the-treatment-of-osteosarcoma 2018-09-17T08:30:10-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/188/cellectar-biosciences-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference 2018-08-29T08:30:10-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/187/fractionated-dosing-improves-tolerability-and-safety-of-cellectars-clr-131-in-rr-multiple-myeloma-patients 2018-08-20T08:30:10-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/186/cellectars-clr-131-receives-fda-rare-pediatric-disease-designation-for-the-treatment-of-ewings-sarcoma 2018-08-13T08:00:37-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/185/cellectar-reports-2018-second-quarter-financial-results-and-provides-business-update 2018-08-10T08:00:13-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/184/cellectar-biosciences-announces-closing-of-16-56-million-underwritten-public-offering-and-full-exercise-of-over-allotment-option 2018-07-31T16:05:07-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/183/cellectar-biosciences-announces-pricing-of-14-4-million-underwritten-public-offering 2018-07-27T08:30:12-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/182/cellectar-reports-positive-phase-2-interim-data-for-clr-131-in-relapsedrefractory-dlbcl-patients 2018-07-18T08:00:05-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/181/cellectar-reports-94-reduction-in-overall-tumor-volume-in-waldenstrom-macroglobulinemia-patient-in-phase-2-clr-131-clinical-study 2018-07-17T08:00:17-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/180/cellectar-announces-1-for-10-reverse-stock-split 2018-07-13T16:05:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/179/cellectars-clr-131-receives-fda-orphan-drug-designation-for-treatment-of-ewings-sarcoma 2018-07-09T08:00:16-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/178/cellectar-announces-expansion-of-diffuse-large-b-cell-lymphoma-cohort-in-clr-131-phase-2-trial 2018-06-28T08:06:08-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/177/cellectar-granted-u-s-patent-for-the-treatment-of-various-cancers-and-cancer-stem-cells-with-clr-131 2018-06-07T08:30:05-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/176/fda-grants-rare-pediatric-disease-designation-to-cellectar-biosciences-clr-131-for-the-treatment-of-rhabdomyosarcoma 2018-06-06T08:00:11-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/175/cellectar-reports-recent-corporate-highlights-and-2018-first-quarter-financial-results 2018-05-11T08:00:05-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/174/cellectar-granted-orphan-drug-designation-for-clr-131-to-treat-rhabdomyosarcoma 2018-05-09T14:28:17-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/173/cellectar-receives-rare-pediatric-disease-designation-for-clr-131-to-treat-neuroblastoma 2018-05-02T08:00:16-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/172/cellectar-presents-preclinical-data-at-aacr-annual-meeting-demonstrating-efficacy-of-fractionated-injections-of-clr-131-in-multiple-myeloma 2018-04-17T08:00:12-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/171/cellectar-presents-preclinical-data-at-aacr-annual-meeting-demonstrating-the-ability-of-its-pdcs-to-selectively-target-a-broad-range-of-tumor-cells 2018-04-16T08:05:04-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/170/preclinical-data-highlighting-uptake-and-enhanced-anti-tumor-effects-of-cellectars-clr-131-in-head-and-neck-cancer-presented-at-aacr-annual-meeting 2018-04-16T08:00:07-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/169/cellectar-biosciences-appoints-brian-m-posner-as-chief-financial-officer 2018-04-04T08:00:13-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/168/cellectar-announces-issuance-of-u-s-patent-covering-clr-131-use-in-multiple-myeloma 2018-04-03T08:00:12-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/167/cellectar-granted-seminal-u-s-patent-for-phospholipid-ether-analogs-as-cancer-targeting-drug-vehicles 2018-03-27T08:00:25-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/166/cellectar-reports-2017-financial-results-and-provides-a-corporate-update 2018-03-21T16:10:02-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/165/cellectar-biosciences-granted-orphan-drug-designation-for-clr-131-to-treat-neuroblastoma 2018-03-19T08:05:03-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/164/cellectar-biosciences-to-host-2017-financial-results-and-business-update-conference-call-on-march-22-2018 2018-03-19T08:00:08-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/163/cellectar-announces-late-breaking-poster-presentations-at-aacr-2018-featuring-pdcs-and-clr-131 2018-03-15T08:00:37-04:00 https://www.cellectar.com/investors/news-events/press-releases/detail/162/phase-1-clinical-data-demonstrating-clr-124-uptake-in-brain-tumors-accepted-for-oral-presentation-at-the-12th-world-congress-of-the-world-federation-of-nuclear-medicine-and-biology 2018-03-06T08:02:08-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/161/cellectar-biosciences-to-present-at-upcoming-march-conferences 2018-03-05T08:01:09-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/159/cellectar-biosciences-to-present-at-the-2018-bio-ceo-investor-conference 2018-02-08T08:15:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/158/cellectar-receives-uspto-notice-of-allowance-for-patent-covering-use-of-clr-131-in-multiple-myeloma 2018-02-07T08:15:03-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/157/cellectar-initiates-dlbcl-cohort-in-phase-2-trial-of-clr-131-in-refractory-b-cell-hematologic-cancers 2018-01-29T08:00:27-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/5/cellectar-biosciences-to-participate-at-noble-capital-markets-fourteenth-annual-investor-conference 2018-01-22T08:30:53-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/156/cellectar-biosciences-to-participate-at-biotech-showcase-2018 2018-01-23T12:14:18-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/155/cellectar-files-ind-for-phase-1-trial-of-clr-131-in-pediatric-cancers 2018-01-23T12:14:17-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/154/cellectar-announces-expansion-of-relapsedrefractory-multiple-myeloma-cohort-in-phase-2-trial-of-clr-131 2018-01-23T12:14:16-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/153/cellectar-biosciences-to-present-at-the-10th-annual-ld-micro-main-event 2018-01-23T12:14:15-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/152/cellectar-biosciences-reports-third-quarter-2017-financial-and-corporate-performance 2018-01-23T12:14:15-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/151/cellectar-announces-updated-median-overall-survival-of-26-2-months-from-cohort-1-of-clr-131-phase-1-trial-in-advanced-multiple-myeloma 2018-01-23T12:14:13-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/150/cellectar-biosciences-to-host-conference-call-on-november-10-2017-to-report-third-quarter-2017-financial-results-and-corporate-performance 2018-01-23T12:14:12-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/149/new-preclinical-data-suggest-that-cellectar-biosciences-pdc-platform-provides-enhanced-outcomes-in-combination-with-external-radiation 2018-01-23T12:14:12-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/148/cellectar-biosciences-introduces-multiple-dose-regimen-in-fifth-cohort-of-phase-1-trial-of-clr-131-in-multiple-myeloma 2018-01-23T12:14:11-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/147/cellectar-biosciences-receives-additional-japanese-patent-for-clr-131-and-clr-125-for-the-treatment-of-various-solid-tumors 2018-01-23T12:14:09-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/146/cellectar-biosciences-announces-successful-completion-of-7-76-million-registered-direct-offering 2018-01-23T12:14:09-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/145/cellectar-biosciences-announces-7-76-million-registered-directoffering-priced-at-the-market 2018-01-23T12:14:08-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/144/cellectar-biosciences-and-pierre-fabre-extend-collaboration-for-development-of-new-phospholipid-drug-conjugates 2018-01-23T12:14:07-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/143/cellectar-biosciences-to-present-at-the-microcap-conference 2018-01-23T12:14:06-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/142/cellectar-biosciences-reports-cohort-four-data-and-partial-response-in-relapsed-or-refractory-multiple-myeloma-patient-treated-with-clr-131 2018-01-23T12:14:06-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/141/cellectar-biosciences-enters-into-strategic-collaboration-with-onconova-therapeutics-to-develop-new-phospholipid-drug-conjugates 2018-01-23T12:14:05-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/140/cellectar-biosciences-to-present-at-the-ladenburg-thalmann-2017-healthcare-conference 2018-01-23T12:14:04-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/139/cellectar-biosciences-appoints-jarrod-longcor-chief-business-officer 2018-01-23T12:14:03-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/138/cellectar-biosciences-to-present-at-the-19th-annual-rodman-and-renshaw-global-investment-conference 2018-01-23T12:14:03-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/137/cellectar-biosciences-announces-significant-pdc-platform-advancement-demonstrates-potential-to-improve-therapeutic-window 2018-01-23T12:14:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/136/cellectar-biosciences-reports-second-quarter-2017-financial-and-corporate-performance 2018-01-23T12:14:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/135/cellectar-biosciences-clr-131-achieves-overall-survival-of-greater-than-22-months-in-advanced-multiple-myeloma-patients 2018-01-23T12:14:00-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/134/cellectar-biosciences-to-host-conference-call-on-august-14-2017-to-report-second-quarter-2017-financial-results-and-corporate-performance 2018-01-23T12:13:59-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/133/cellectar-biosciences-signs-collaboration-with-avicenna-oncology-to-develop-new-pdcs-for-solid-tumors 2018-01-23T12:13:59-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/132/cellectar-biosciences-to-present-at-the-2017-marcum-microcap-conference 2018-01-23T12:13:57-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/131/cellectar-biosciences-to-present-at-the-ld-micro-invitational-conference 2018-01-23T12:13:56-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/130/three-abstracts-on-dosing-regimens-of-cellectars-clr-131-in-a-variety-of-tumor-types-published-in-the-2017-asco-annual-meeting-proceedings 2018-01-23T12:13:56-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/129/cellectar-biosciences-reports-first-quarter-2017-financial-and-corporate-performance 2018-01-23T12:13:55-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/128/cellectar-biosciences-to-host-conference-call-on-may-11-2017-to-report-first-quarter-2017-financial-results-and-corporate-performance 2018-01-23T12:13:54-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/127/cellectars-radiotherapeutic-pdcs-demonstrate-an-increased-survival-benefit-using-multiple-doses-in-preclinical-studies 2018-01-23T12:13:53-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/126/cellectar-biosciences-receives-additional-u-s-patents-for-pdc-optical-agents-in-the-detection-of-multiple-cancers 2018-01-23T12:13:52-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/125/updated-cellectar-biosciences-strengthens-management-team-with-appointment-of-john-friend-m-d-as-chief-medical-officer 2018-01-23T12:13:52-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/124/cellectar-biosciences-receives-japanese-patent-for-clr-131-and-clr-125-for-the-treatment-of-cancer-stem-cells 2018-01-23T12:13:51-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/123/cellectar-biosciences-strengthens-management-team-with-appointment-of-john-friend-m-d-as-chief-medical-officer 2018-01-23T12:13:50-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/122/cellectar-biosciences-adds-industry-veterans-douglas-swirsky-and-frederick-driscoll-to-its-board-of-directors 2018-01-23T12:13:49-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/121/after-much-anticipation-cellectar-biosciences-initiates-nci-supported-phase-ii-trial-of-clr-131-in-multiple-myeloma-and-other-blood-cancers 2018-01-23T12:13:49-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/120/cellectar-biosciences-further-deepens-intellectual-property-portfolio-with-patent-grant-for-pet-imaging-pdc 2018-01-23T12:13:48-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/119/cellectar-biosciences-reports-2016-company-performanceand-continued-progress-in-first-quarter-2017 2018-01-23T12:13:47-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/118/newly-issued-japanese-patent-for-pdc-optical-agents-further-strengthens-cellectar-biosciences-intellectual-property-portfolio 2018-01-23T12:13:46-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/117/cellectar-biosciences-to-host-conference-call-on-march-15-to-report-fourth-quarter-and-year-end-2016-financial-results-and-corporate-performance 2018-01-23T12:13:45-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/116/expanding-its-strategic-relationship-with-wisconsin-alumni-research-foundation-warf-cellectar-biosciences-executes-new-license-agreement 2018-01-23T12:13:45-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/115/cellectar-biosciences-to-present-at-29th-annual-roth-conference 2018-01-23T12:13:44-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/114/cellectar-biosciences-provides-phase-i-trial-update-of-clr-131-in-multiple-myeloma-median-progression-free-survival-extends-to-133-days-median-overall-survival-reaches-17-7-months 2018-01-23T12:13:43-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/113/upon-successful-completion-of-cohort-3-cellectar-biosciences-initiates-fourth-cohort-of-its-phase-i-clinical-trial-of-clr-131-in-multiple-myeloma 2018-01-23T12:13:43-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/112/update----cellectar-biosciences-to-present-at-2017-bio-ceo-investor-conference 2018-01-23T12:13:42-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/111/cellectar-biosciences-to-present-at-2017-bio-ceo-investor-conference 2018-01-23T12:13:41-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/110/cellectar-biosciences-announces-two-peer-reviewed-studies-demonstrating-the-capabilities-of-the-pdc-platform 2018-01-23T12:13:40-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/109/cellectar-biosciences-to-present-at-noblecon13 2018-01-23T12:13:39-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/108/cellectar-biosciences-announces-additional-us-patent-granted-for-clr-131-and-clr-125-in-a-broad-range-of-solid-tumors 2018-01-23T12:13:39-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/107/cellectar-biosciences-to-present-at-the-9th-annual-biotech-showcase 2018-01-23T12:13:38-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/106/cellectar-biosciences-announces-us-and-japanese-patent-allowances-for-diagnostic-and-optical-imaging-pdcs 2018-01-23T12:13:37-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/105/cellectar-biosciences-announces-uspto-grants-patent-allowances-for-radiotherapeutic-pdcs-for-a-variety-of-solid-tumor-types 2018-01-23T12:13:37-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/104/cellectar-biosciences-announces-uspto-grants-patent-for-paclitaxel-pdc-provides-additional-patent-protection-for-select-solid-tumors-through-2035 2018-01-23T12:13:36-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/103/cellectar-biosciences-presents-poster-at-the-58th-annual-meeting-of-the-american-society-of-hematology 2018-01-23T12:13:35-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/102/cellectar-biosciences-announces-results-from-the-first-two-cohorts-of-its-clr-131-phase-1-trial-demonstrates-excellent-efficacy-overall-survival-benefit-and-progression-free-survival-similar-to-or-better-than-recently-approved-therapies 2018-01-23T12:13:35-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/101/cellectar-biosciences-announces-successful-completion-of-9-2-million-public-offering-which-includes-full-exercise-of-1-2-million-over-allotment-option 2018-01-23T12:13:34-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/100/cellectar-biosciences-announces-partnership-with-radiopharmaceutical-specialists-cpdc-to-establish-manufacturing-capacity-in-anticipation-of-clr-131-pivotal-trial-and-commercial-production 2018-01-23T12:13:33-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/99/cellectar-biosciences-announces-pricing-of-8000000-public-offering 2018-01-23T12:13:32-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/98/cellectar-biosciences-announces-successful-conjugation-of-multiple-pierre-fabre-cytotoxic-compounds-to-pdc-delivery-platform-initiates-in-vivo-studies-for-solid-tumors 2018-01-23T12:13:30-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/97/cellectar-biosciences-announces-inc-research-as-the-cro-for-the-phase-ii-trial-of-clr-131-in-hematologic-malignancies-2m-nci-grant-covers-half-of-study-cost-with-potential-option-to-pursue-additional-3m-for-pivotal-trial 2018-01-23T12:13:29-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/96/update----cellectar-biosciences-announces-recent-key-accomplishments-and-third-quarter-2016-financial-results 2018-01-23T12:13:28-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/95/cellectar-biosciences-announces-recent-key-accomplishments-and-third-quarter-2016-financial-results 2018-01-23T12:13:28-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/94/cellectar-biosciences-to-host-conference-call-on-november-11-to-report-third-quarter-2016-financial-results-and-corporate-performance 2018-01-23T12:13:27-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/93/cellectar-biosciences-announces-design-for-nci-supported-phase-ii-study-of-clr-131-in-multiple-myeloma-and-other-hematologic-malignancies 2018-01-23T12:13:26-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/92/cellectar-biosciences-announces-data-on-clr-131-accepted-for-poster-presentation-at-the-58th-annual-american-society-of-hematology-meeting-exposition 2018-01-23T12:13:26-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/91/cellectar-biosciences-to-present-at-bio-investor-forum 2018-01-23T12:13:24-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/90/cellectar-biosciences-to-present-at-seethru-equity-and-dawson-james-investor-conferences 2018-01-23T12:13:23-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/89/cellectar-biosciences-announces-enrollment-of-first-patient-into-third-cohort-of-its-phase-i-clinical-study-of-clr-131-in-multiple-myeloma 2018-01-23T12:13:23-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/88/cellectar-biosciences-announces-uspto-issues-formal-patent-allowance-for-clr-1603 2018-01-23T12:13:22-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/87/cellectar-biosciences-announces-new-positive-data-from-phase-i-clinical-study-of-clr-131-in-multiple-myeloma 2018-01-23T12:13:21-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/86/cellectar-biosciences-to-present-at-oktoberinvestfest 2018-01-23T12:13:21-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/85/cellectar-biosciences-to-present-at-ladenburg-thalmann-2016-healthcare-conference 2018-01-23T12:13:20-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/84/cellectar-biosciences-announces-lead-compound-clr-131-to-be-studied-in-head-and-neck-cancer-in-12m-university-of-wisconsin-spore-grant 2018-01-23T12:13:19-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/83/cellectar-biosciences-to-present-at-the-18th-annual-rodman-renshaw-global-investment-conference 2018-01-23T12:13:19-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/82/update----cellectar-biosciences-announces-recent-key-accomplishments-and-second-quarter-2016-financial-results 2018-01-23T12:13:18-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/81/cellectar-biosciences-announces-recent-key-accomplishments-and-second-quarter-2016-financial-results 2018-01-23T12:13:17-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/80/cellectar-biosciences-to-host-conference-call-on-august-15-to-report-second-quarter-2016-financial-results-and-corporate-performance 2018-01-23T12:13:16-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/79/cellectar-biosciences-announces-2-million-nci-sbir-contract-for-a-phase-2-clinical-study 2018-01-23T12:13:15-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/78/cellectar-biosciences-appoints-jarrod-longcor-senior-vice-president-of-corporate-development-and-operations 2018-01-23T12:13:14-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/77/cellectar-biosciences-announces-results-of-nci-sponsored-study-of-clr-125-showing-potential-effect-against-triple-negative-breast-cancer 2018-01-23T12:13:13-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/76/cellectar-biosciences-announces-results-of-in-vivo-study-demonstrating-pdc-platform-delivery-of-paclitaxel-to-be-superior-in-tumor-targeting-to-free-paclitaxel 2018-01-23T12:13:12-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/75/cellectar-biosciences-announces-uspto-issues-patent-for-its-radiotherapeutic-pdc-portfolio-further-strengthening-and-expanding-protection-for-its-delivery-platform 2018-01-23T12:13:11-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/74/cellectar-biosciences-announces-uspto-issues-patent-for-new-phospholipid-drug-conjugate-pdc-with-paclitaxel 2018-01-23T12:13:11-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/73/cellectar-biosciences-to-present-at-the-5th-annual-seethru-equity-microcap-investor-conference 2018-01-23T12:13:10-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/72/cellectar-biosciences-to-present-at-the-2016-marcum-microcap-conference 2018-01-23T12:13:09-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/71/cellectar-biosciences-patent-application-for-phospholipid-ether-analogs-as-cancer-targeting-drug-vehicles-published-by-uspto 2018-01-23T12:13:09-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/70/cellectar-biosciences-satisfies-all-nasdaq-listing-criteria 2018-01-23T12:13:08-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/69/cellectar-biosciences-announces-first-quarter-2016-financial-results 2018-01-23T12:13:07-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/68/cellectar-biosciences-to-host-conference-call-on-may-12-2016-to-report-first-quarter-2016-financial-results-and-provide-a-corporate-performance-update 2018-01-23T12:13:07-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/67/cellectar-biosciences-announces-successful-completion-of-8-million-public-offering 2018-01-23T12:13:06-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/66/cellectar-biosciences-announces-pricing-of-7000000-public-offering 2018-01-23T12:13:05-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/65/cellectar-biosciences-receives-positive-nasdaq-listing-determination 2018-01-23T12:13:04-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/64/cellectar-biosciences-announces-year-end-2015-financial-results 2018-01-23T12:13:04-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/63/cellectar-biosciences-to-present-at-the-28th-annual-roth-capital-conference 2018-01-23T12:13:03-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/62/cellectar-biosciences-to-host-conference-call-on-march-10-to-report-year-end-2015-financials-corporate-performance-and-2016-objectives 2018-01-23T12:13:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/61/cellectar-biosciences-announces-1-for-10-reverse-stock-split 2018-01-23T12:13:02-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/60/cellectar-biosciences-to-present-at-the-2016-biotech-showcase 2018-01-23T12:13:01-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/59/cellectar-biosciences-announces-positive-data-from-phase-1-therapeutic-trial-of-clr-131-in-multiple-myeloma 2018-01-23T12:13:00-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/160/cellectar-biosciences-and-pierre-fabre-laboratories-announce-oncology-research-collaboration 2018-02-20T06:20:22-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/58/cellectar-biosciences-to-provide-update-on-phase-1-multiple-myeloma-study 2018-01-23T12:12:59-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/57/cellectar-biosciences-chief-scientific-officer-receives-international-recognition-for-pioneering-research 2018-01-23T12:12:58-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/56/cellectar-biosciences-announces-third-quarter-financial-results 2018-01-23T12:12:57-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/55/cellectar-biosciences-converts-patent-application-for-phospholipid-ether-analogs-as-cancer-targeting-drug-vehicles 2018-01-23T12:12:56-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/54/cellectar-biosciences-to-host-conference-call-on-november-12th-to-discuss-third-quarter-financial-results-and-provide-clinical-development-program-update 2018-01-23T12:12:56-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/53/cellectar-biosciences-provides-phospholipid-drug-conjugate-pdc-platform-development-update 2018-01-23T12:12:55-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/52/cellectar-biosciences-to-present-at-the-2015-bio-investor-forum 2018-01-23T12:12:54-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/51/cellectar-biosciences-closes-on-3-3-million-financing 2018-01-23T12:12:54-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/50/cellectar-biosciences-awarded-2-3m-national-cancer-institute-fast-track-sbir-grant-to-advance-phospholipid-drug-conjugate-pdc-delivery-platform 2018-01-23T12:12:53-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/49/cellectar-biosciences-announces-pricing-of-3-3-million-financing 2018-01-23T12:12:52-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/48/cellectar-biosciences-to-present-at-the-ladenburg-thalmann-2015-healthcare-conference 2018-01-23T12:12:52-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/47/cellectar-biosciences-to-present-at-the-rodman-renshaw-17th-annual-global-investment-conference 2018-01-23T12:12:51-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/46/cellectar-biosciences-introduces-phospholipid-ether-drug-conjugate-pdc-platform-for-targeted-delivery-of-chemotherapeutics 2018-01-23T12:12:50-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/45/cellectar-biosciences-announces-2nd-quarter-financial-results 2018-01-23T12:12:50-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/44/cellectar-biosciences-to-host-conference-call-on-august-12th-to-discuss-second-quarter-financial-results-and-provide-update-on-development-plans 2018-01-23T12:12:49-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/43/cellectar-appoints-industry-veteran-jim-caruso-president-and-chief-executive-officer 2018-01-23T12:12:49-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/42/cellectar-biosciences-announces-clr1502-development-program-to-be-classified-as-combination-product-by-u-s-food-and-drug-administration 2018-01-23T12:12:48-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/41/cellectar-biosciences-announces-intent-to-adjourn-annual-meeting-of-stockholders 2018-01-23T12:12:47-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/40/cellectar-biosciences-reports-first-quarter-2015-financial-results-and-provides-update-on-clinical-programs 2018-01-23T12:12:47-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/39/cellectar-biosciences-to-host-conference-call-on-may-21st-to-discuss-first-quarter-2015-results-and-provide-update-on-development-programs 2018-01-23T12:12:46-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/38/cellectar-biosciences-reschedules-release-of-first-quarter-financials-and-quarterly-conference-call 2018-01-23T12:12:44-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/37/cellectar-biosciences-to-host-conference-call-on-may-12th-to-discuss-first-quarter-2015-results-and-provide-update-on-development-programs 2018-01-23T12:12:44-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/36/cellectar-biosciences-initiates-proof-of-concept-trial-of-i-131-clr1404-in-multiple-myeloma 2018-01-23T12:12:43-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/33/cellectar-biosciences-full-year-2014-financial-results-and-recent-highlights 2018-01-23T12:12:41-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/35/cellectar-biosciences-to-host-conference-call-on-march-24th-to-discuss-fourth-quarter-and-full-year-2014-results-and-provide-update-on-development-progress 2018-01-23T12:12:43-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/34/cellectar-biosciences-to-present-at-27th-annual-roth-conference 2018-01-23T12:12:41-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/32/cellectar-biosciences-to-present-at-the-17th-annual-bio-ceo-investor-conference-2015 2018-01-23T12:12:40-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/30/peer-reviewed-glioma-surgery-study-with-cellectar-biosciences-fluorescence-cancer-targeting-agents-chosen-for-the-cover-of-neurosurgery 2018-01-23T12:12:38-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/31/cellectar-biosciences-to-present-at-the-biotech-showcase-2015-conference 2018-01-23T12:12:39-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/29/cellectar-biosciences-granted-orphan-designation-for-i-131-clr1404-for-the-treatment-of-multiple-myeloma 2018-01-23T12:12:38-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/26/cellectar-biosciences-names-cameron-szakacs-ph-d-vice-president-of-clinical-development 2018-01-23T12:12:36-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/27/cellectar-biosciences-reports-third-quarter-2014-financial-results-and-recent-highlights 2018-01-23T12:12:36-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/28/cellectar-biosciences-to-host-conference-call-on-november-11th-to-discuss-third-quarter-2014-results-and-provide-quarterly-update-on-development-progress 2018-01-23T12:12:37-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/25/cellectar-biosciences-announces-publication-of-findings-demonstrating-efficacy-of-its-phospholipid-ether-analog-platform-in-detecting-colorectal-cancer 2018-01-23T12:12:35-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/23/cellectar-biosciences-announces-participation-in-two-upcoming-investor-conferences-in-september 2018-01-23T12:12:34-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/24/cellectar-biosciences-announces-acceptance-of-investigational-new-drug-application-to-evaluate-i-131-clr1404-in-clinical-trials-in-relapsed-or-refractory-multiple-myeloma 2018-01-23T12:12:34-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/22/cellectar-biosciences-reports-second-quarter-2014-financial-results-and-recent-highlights 2018-01-23T12:12:33-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/18/cellectar-biosciences-announces-closing-of-public-offering-and-partial-exercise-of-underwriters-over-allotment-option 2018-01-23T12:12:30-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/21/cellectar-biosciences-to-host-conference-call-on-august-20th-to-discuss-second-quarter-2014-results-and-provide-quarterly-update-on-development-progress 2018-01-23T12:12:32-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/19/cellectar-biosciences-announces-pricing-of-12500000-public-offering-and-listing-on-the-nasdaq-capital-market 2018-01-23T12:12:31-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/20/cellectar-biosciences-files-investigational-new-drug-application-to-evaluate-i-131-clr1404-in-clinical-trials-in-relapsed-or-refractory-multiple-myeloma 2018-01-23T12:12:32-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/17/cellectar-biosciences-announces-1-for-20-reverse-stock-split-and-reduction-in-authorized-shares-of-common-stock 2018-01-23T12:12:30-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/15/cellectar-biosciences-announces-presentations-at-2014-american-society-of-clinical-oncology-asco-annual-meeting 2018-01-23T12:12:28-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/16/cellectar-biosciences-appoints-chad-j-kolean-chief-financial-officer 2018-01-23T12:12:29-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/14/cellectar-biosciences-reports-first-quarter-2014-financial-results-and-recent-highlights 2018-01-23T12:12:28-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/12/cellectar-biosciences-to-host-conference-call-on-may-14th-to-discuss-first-quarter-2014-results-and-provide-quarterly-update-on-development-progress 2018-01-23T12:12:27-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/13/cellectar-biosciences-announces-receipt-of-orphan-designation-of-i-124-clr1404-as-diagnostic-for-the-management-of-glioma-from-u-s-food-and-drug-administration 2018-01-23T12:12:27-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/11/dr-simon-pedder-becomes-president-and-chief-executive-officer-of-cellectar-biosciences 2018-01-23T12:12:26-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/8/cellectar-biosciences-full-year-2013-financial-results-and-recent-highlights 2018-01-23T12:12:24-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/9/cellectar-biosciences-to-host-conference-call-on-march-25th-to-discuss-full-year-2013-financial-results-and-provide-quarterly-update-on-development-progress 2018-01-23T12:12:25-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/10/cellectar-announces-initiation-of-phase-ii-imaging-trial-with-i-124-clr1404-in-patients-with-newly-diagnosed-or-recurrent-glioblastoma 2018-01-23T12:12:25-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/7/correcting-and-replacing----novelos-therapeutics-announces-corporate-name-change-to-cellectar-biosciences-inc 2018-01-23T12:12:23-05:00 https://www.cellectar.com/investors/news-events/press-releases/detail/6/novelos-therapeutics-announces-corporate-name-change-to-cellectar-biosciences-inc 2018-01-23T12:12:22-05:00 https://www.cellectar.com/investors/news-events/ir-calendar/detail/20260304-fourth-quarter-and-full-year-2025-earnings-call 2026-02-25T08:07:25-05:00 https://www.cellectar.com/investors/news-events/ir-calendar/detail/20260113-44th-annual-jp-morgan-healthcare-conference 2026-01-09T08:18:40-05:00 https://www.cellectar.com/investors/news-events/ir-calendar/detail/20251113-third-quarter-2025-earnings-call 2025-11-06T09:09:27-05:00 https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001104659-26-023169/tm267955d1_8k.htm 2026-03-04T07:24:15-05:00 https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001104659-26-023167/clrb-20251231x10k.htm 2026-03-04T07:23:00-05:00 https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001420506-26-000425/primary_doc.html 2026-02-13T16:45:12-05:00 https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001622627-26-000002/primary_doc.html 2026-02-10T15:24:01-05:00 https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001753926-26-000263/primary_doc.html 2026-02-04T16:11:52-05:00 https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001104659-25-121691/tm2533642-1_4seq1.html 2025-12-16T18:00:38-05:00 https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001104659-25-114989/tm2529020d2_424b3.htm 2025-11-21T16:06:06-05:00 https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001420506-25-003303/primary_doc.html 2025-11-14T10:47:20-05:00 https://www.cellectar.com/contact-us https://www.cellectar.com/about-us https://www.cellectar.com/terms-of-use https://www.cellectar.com/privacy-policy https://www.cellectar.com/disclaimer https://www.cellectar.com/accessibility-policy https://www.cellectar.com/sitemap